Читать книгу Recent Advances in the Pathogenesis and Treatment of Kidney Diseases - Группа авторов - Страница 28

1Yokoyama H, Sugiyama H, Sato H, et al: Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 2012;16:903–920.

2Takei T, Koike M, Suzuki K, et al: The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 2007;11:214–217.

3Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;2:556–560.

4Araya C, Diaz L, Wasserfall C, et al: T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2009;24:1691–1698.

5Audard V, Pawlak A, Candelier M, et al: Upregulation of nuclear factor-related kappa B suggests a disorder of transcriptional regulation in minimal change nephrotic syndrome. PLoS One 2012;7:e30523.

6Takei T, Nitta K: Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin Exp Nephrol 2011;15:641–647.

7Kamei K, Ito S, Nozu K, et al: Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321–1328.

8Tobinai K, Kobayashi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998;9:527–534.

9Vieira CA, Agarwal A, Book BK, et al: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1 safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77:542–548.

10Genberg H, Hansson A, Wernerson A, et al: Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6:2418–2428.

11McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.

12Sidner RA, Book BK, Agarwal A, et al: In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004;13:55–62.

13Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012;82:840–856.

14Munyentwali H, Bouachi K, Audard V, et al: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013;83:511–516.

15Guitard J, Hebral AL, Fakhouri F, et al: Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant 2014;29:2084–2091.

16Takei T, Itabashi M, Moriyama T, et al: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013;28:1225–1232.

17Iwabuchi Y, Takei T, Moriyama T, et al: Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 2014;93:e300.

18Miyabe Y, Takei T, Iwabuchi Y, et al: Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Clin Exp Nephrol 2016;20:103–110.

19Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K: Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Nephrol 2013;38:483–488.

20Ito S, Kamei K, Ogura M, et al: Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011;26:1823–1828.

21Takura T, Takei T, Nitta K: Cost-effectiveness of administering rituximab for steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome: a preliminary study in Japan. Sci Rep 2017;7:46036.

Kosaku Nitta, MD, PhD

Department of Medicine, Kidney Center

Tokyo Women’s Medical University

8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 (Japan)

E-Mail knitta@twmu.ac.jp